Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Author
Isenberg, DSturgess, J
Allen, E
Aranow, C
Askanase, A
Sang-Cheol, B
Bernatsky, S
Bruce, I
Buyon, J
Cervera, R
Clarke, A
Dooley, Mary Anne
Fortin, P
Ginzler, E
Gladman, D
Hanly, J
Inanc, M
Jacobsen, S
Kamen, D
Khamashta, M
Lim, S
Manzi, S
Nived, O
Peschken, C
Petri, M
Kalunian, K
Rahman, A
Ramsey-Goldman, R
Romero-Diaz, J
Ruiz-Irastorza, G
Sanchez-Guerrero, J
Steinsson, K
Sturfelt, G
Urowitz, M
van Vollenhoven, R
Wallace, D J
Zoma, A
Merrill, J
Gordon, C
Journal title
Arthritis care & researchDate Published
2017-12-08Publication Volume
70Publication Issue
1Publication Begin page
98Publication End page
103
Metadata
Show full item recordAbstract
To determine the level of agreement of disease flare severity (distinguishing severe, moderate, and mild flare and persistent disease activity) in a large paper-patient exercise involving 988 individual cases of systemic lupus erythematosus.A total of 988 individual lupus case histories were assessed by 3 individual physicians. Complete agreement about the degree of flare (or persistent disease activity) was obtained in 451 cases (46%), and these provided the reference standard for the second part of the study. This component used 3 flare activity instruments (the British Isles Lupus Assessment Group [BILAG] 2004, Safety of Estrogens in Lupus Erythematosus National Assessment [SELENA] flare index [SFI] and the revised SELENA flare index [rSFI]). The 451 patient case histories were distributed to 18 pairs of physicians, carefully randomized in a manner designed to ensure a fair case mix and equal distribution of flare according to severity.
The 3-physician assessment of flare matched the level of flare using the 3 indices, with 67% for BILAG 2004, 72% for SFI, and 70% for rSFI. The corresponding weighted kappa coefficients for each instrument were 0.82, 0.59, and 0.74, respectively. We undertook a detailed analysis of the discrepant cases and several factors emerged, including a tendency to score moderate flares as severe and persistent activity as flare, especially when the SFI and rSFI instruments were used. Overscoring was also driven by scoring treatment change as flare, even if there were no new or worsening clinical features.
Given the complexity of assessing lupus flare, we were encouraged by the overall results reported. However, the problem of capturing lupus flare accurately is not completely solved.
Citation
Isenberg D, Sturgess J, Allen E, Aranow C, Askanase A, Sang-Cheol B, Bernatsky S, Bruce I, Buyon J, Cervera R, Clarke A, Dooley MA, Fortin P, Ginzler E, Gladman D, Hanly J, Inanc M, Jacobsen S, Kamen D, Khamashta M, Lim S, Manzi S, Nived O, Peschken C, Petri M, Kalunian K, Rahman A, Ramsey-Goldman R, Romero-Diaz J, Ruiz-Irastorza G, Sanchez-Guerrero J, Steinsson K, Sturfelt G, Urowitz M, van Vollenhoven R, Wallace DJ, Zoma A, Merrill J, Gordon C. Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. Arthritis Care Res (Hoboken). 2018 Jan;70(1):98-103. doi: 10.1002/acr.23252. Epub 2017 Dec 8. PMID: 28388813; PMCID: PMC5767751.DOI
10.1002/acr.23252ae974a485f413a2113503eed53cd6c53
10.1002/acr.23252
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as © 2017, The Authors. Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology.
Related articles
- An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA.
- Authors: Isenberg DA, Allen E, Farewell V, D'Cruz D, Alarcón GS, Aranow C, Bruce IN, Dooley MA, Fortin PR, Ginzler EM, Gladman DD, Hanly JG, Inanc M, Kalunian K, Khamashta M, Merrill JT, Nived O, Petri M, Ramsey-Goldman R, Sturfelt G, Urowitz M, Wallace DJ, Gordon C, Rahman A
- Issue date: 2011 Jan
- Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
- Authors: Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW, BLISS-52 and BLISS-76 Study Groups
- Issue date: 2013 Aug
- How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.
- Authors: Thanou A, Chakravarty E, James JA, Merrill JT
- Issue date: 2014 Dec
- Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients.
- Authors: FitzGerald JD, Grossman JM
- Issue date: 1999
- Preliminary criteria for global flares in childhood-onset systemic lupus erythematosus.
- Authors: Brunner HI, Mina R, Pilkington C, Beresford MW, Reiff A, Levy DM, Tucker LB, Eberhard BA, Ravelli A, Schanberg LE, Saad-Magalhaes C, Higgins GC, Onel K, Singer NG, von Scheven E, Itert L, Klein-Gitelman MS, Punaro M, Ying J, Giannini EH
- Issue date: 2011 Sep